Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell Holdings PLC teams up with Sweden's leading research organisation

Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.
Scancell Holdings PLC teams up with Sweden's leading research organisation
The scientists are looking to share information.

Drug developer Scancell Holdings PLC (LON:SCLP) is teaming up with Sweden’s leading research organisation -  a collaboration that may aid the development of one of its two breakthrough technologies.

Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.

These particular proteins are more commonly associated with arthritis, though Scancell’s work suggests they are key to tumour growth.

This avenue of research led the company to develop the Moditope platform technology that overcomes the immune suppression induced by tumours themselves.

The work of professors Lars Klareskog and Vivianne Malmström, of the Karolinska Institutet, has focused on rheumatoid arthritis.

“We believe that this strategic collaboration with Karolinska will enhance our joint understanding of the role that citrullination plays in both cancer and rheumatoid arthritis, and will help us develop the Moditope platform to its full potential," said professor Lindy Durrant, joint chief executive of Scancell who is also Professor of Cancer Immunotherapy at Nottingham University.

Ian_55ae0ddd437b7.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Newswire
January 31 2017

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
Dimerix: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Kathy Harrison talked pending milestone news with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use